US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

OPUS GENETICS INC

6.04

-0.0300-0.49%

Pre-market: 5.95-0.0900-1.49%07:41 EDT

Volume:4.66M

Turnover:28.44M

Market Cap:502.50M

PE:-4.67

High:6.58

Open:6.16

Low:5.77

Close:6.07

52wk High:7.07

52wk Low:1.35

Shares:83.20M

Float Shares:64.45M

Volume Ratio:0.33

T/O Rate:7.23%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.2925

EPS(LYR):-0.8000

ROE:-4796.52%

ROA:-48.06%

PB:-38.70

PE(LYR):-7.55

Loading ...

Overview Company News Filings

Piper Sandler Sticks to Its Buy Rating for Opus Genetics (IRD)

Opus Genetics Initiated at Market Outperform by Citizens

Opus Genetics initiated with an Outperform at Citizens

Opus Genetics to present at ARVO annual meeting

Opus Genetics enters senior secured note deal for up to $155 million

Barinthus Biotherapeutics appoints Douglas Swirsky as CFO effective May 1

Opus Genetics shareholders approved authorized common stock increase to 250 million shares

Analysts Are Bullish on Top Healthcare Stocks: Opus Genetics (IRD), Argenx Se (ARGX)

Opus Genetics to present Phase 3 VEGA-3 presbyopia data at ASCRS meeting

Opus Genetics offers executives excise tax reimbursement under change-in-control bonus agreement

Analysts Have Conflicting Sentiments on These Healthcare Companies: Opus Genetics (IRD) and IQVIA Holdings (IQV)

BRIEF-Opus Genetics Inc Announced Strategic Financing Agreement With Oberland Capital Management Llc

Opus Genetics Inc - Cash Runway Extended Into 2029 With $100 Mln Cash

THOMSON REUTERS

Opus Genetics Inc - New Note Facility Provides Access to Upto $155 Mln Non-Dilutive Funding With $35 Mln Upfront

THOMSON REUTERS

Opus Genetics Inc - up to 10% of Notes Convertible, at Oberland Capital’s Option, Into Co's Stock at $6.72 per Share

THOMSON REUTERS

Opus Genetics Inc: Oberland Capital Committed to Make a $5 Mln Equity Investment in Co's Stock at $4.48/Share

THOMSON REUTERS

Opus Genetics secures up to $155 million Oberland Capital non-dilutive financing facility

Cantor Fitzgerald Initiates Opus Genetics at Overweight With $15 Price Target

MT Newswires Live

Opus Genetics Initiated at Overweight by Cantor Fitzgerald

Bremworth Secures IRD Clearance in Floorscape Acquisition Process

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/IRD/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IRD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IRD\",,,,,undefined,":{"symbol":"IRD","market":"US","secType":"STK","nameCN":"OPUS GENETICS INC","latestPrice":6.04,"timestamp":1789156800000,"preClose":6.07,"halted":0,"volume":4658018,"hourTrading":{"tag":"盘前","latestPrice":5.95,"preClose":6.04,"latestTime":"07:41 EDT","volume":11533,"amount":67871.232147,"timestamp":1789386119599,"change":-0.09,"changeRate":-0.014901,"amplitude":0.049669},"delay":0,"changeRate":-0.004942339373970386,"floatShares":64451400,"shares":83195823,"eps":-1.292468,"marketStatus":"Pre-Mkt","change":-0.03,"latestTime":"09-14 07:42:08 EDT","open":6.16,"high":6.576,"low":5.77,"amount":28443586.032678,"amplitude":0.132784,"askPrice":6.36,"askSize":1890,"bidPrice":5.94,"bidSize":160,"shortable":3,"etf":0,"ttmEps":-1.292468,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789392600000},"marketStatusCode":1,"adr":0,"listingDate":1100235600000,"exchange":"NASDAQ","adjPreClose":6.04,"preHourTrading":{"tag":"盘前","latestPrice":5.95,"preClose":6.04,"latestTime":"07:41 EDT","volume":11533,"amount":67871.232147,"timestamp":1789386119599,"change":-0.09,"changeRate":-0.014901,"amplitude":0.049669},"postHourTrading":{"tag":"盘后","latestPrice":5.9539,"preClose":6.04,"latestTime":"19:58 EDT","volume":24465,"amount":146770.7306,"timestamp":1789171082109,"change":-0.0861,"changeRate":-0.014255,"amplitude":0.034768},"volumeRatio":0.3337138860562516,"optionData":{"bulkOrders":[{"symbol":"IRD","call":true,"expireDate":1789704000000,"strike":"7.5","timestamp":1789137478614,"price":0.15,"volume":2000,"amount":30000,"type":"+"},{"symbol":"IRD","call":true,"expireDate":1789704000000,"strike":"5.0","timestamp":1789137478614,"price":1.15,"volume":1062,"amount":122130,"type":"-"}]},"impliedVol":1.3364,"impliedVolPercentile":0.408},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IRD\",,,,,undefined,":{"symbol":"IRD","floatShares":64451400,"roa":"-48.06%","roe":"-4796.52%","lyrEps":-0.8,"volumeRatio":0.3337138860562516,"shares":83195823,"dividePrice":0,"high":6.576,"amplitude":0.132784,"preClose":6.07,"low":5.77,"week52Low":1.35,"pbRate":"-38.70","psRate":"50.98","week52High":7.07,"institutionHeld":0,"latestPrice":6.04,"committee":-0.843902,"eps":-1.292468,"divideRate":0,"volume":4658018,"delay":0,"ttmEps":-1.292468,"open":6.16,"prevYearClose":2.01,"prevWeekClose":6.04,"prevMonthClose":3.62,"prevQuarterClose":4.11,"fiveDayClose":4.6,"twentyDayClose":3.72,"sixtyDayClose":3.9},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IRD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"IRD","fiscalQuarterEnding":"2026/06","expectedEps":-0.15,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"pre","actualEps":-0.14},{"market":"US","date":"2026-05-12","symbol":"IRD","fiscalQuarterEnding":"2026/03","expectedEps":-0.16,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"pre","actualEps":-0.75},{"market":"US","date":"2026-03-10","symbol":"IRD","fiscalQuarterEnding":"2025/12","expectedEps":-0.11,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773115200000,"reportTimeType":"pre","actualEps":-0.14},{"market":"US","date":"2025-11-12","symbol":"IRD","fiscalQuarterEnding":"2025/09","expectedEps":-0.14,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-0.12},{"market":"US","date":"2025-08-13","symbol":"IRD","fiscalQuarterEnding":"2025/06","expectedEps":-0.25,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.12}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IRD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IRD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2778,"buy":0.7222,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7222,"analysts":18,"updateTime":1785384000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IRD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IRD","date":"2026-09-11","current":-4.67323,"percent":0.100858,"low":-8.249622,"twenty":-3.069117,"median":-2.01221,"eighty":-1.133546,"high":-0.560128,"avg":-2.403121,"sd":1.785424,"marketCap":504998645},"quantilePoints":[{"date":"2024-10-31","current":-2.785848,"twenty":-2.857166,"median":-2.64666,"eighty":-2.37374,"marketCap":39294383},{"date":"2024-11-08","current":-2.429259,"twenty":-2.692243,"median":-2.607554,"eighty":-2.476187,"marketCap":34264702},{"date":"2024-11-15","current":-1.225421,"twenty":-2.616468,"median":-2.568551,"eighty":-2.326813,"marketCap":33321637},{"date":"2024-11-22","current":-1.142487,"twenty":-2.607554,"median":-2.49612,"eighty":-1.192247,"marketCap":31066518},{"date":"2024-11-29","current":-1.288651,"twenty":-2.607554,"median":-2.173143,"eighty":-1.193702,"marketCap":35040987},{"date":"2024-12-06","current":-1.323479,"twenty":-2.603096,"median":-1.364112,"eighty":-1.225421,"marketCap":35988040},{"date":"2024-12-13","current":-1.288651,"twenty":-2.574123,"median":-1.335088,"eighty":-1.234669,"marketCap":35040987},{"date":"2024-12-20","current":-1.14597,"twenty":-2.527405,"median":-1.303163,"eighty":-1.16559,"marketCap":31161223},{"date":"2024-12-27","current":-1.253822,"twenty":-2.505202,"median":-1.288651,"eighty":-1.163268,"marketCap":34093933},{"date":"2025-01-03","current":-1.462793,"twenty":-2.49612,"median":-1.294455,"eighty":-1.172556,"marketCap":39776255},{"date":"2025-01-10","current":-1.683372,"twenty":-2.442631,"median":-1.320577,"eighty":-1.181843,"marketCap":45774262},{"date":"2025-01-17","current":-1.346698,"twenty":-2.224366,"median":-1.346698,"eighty":-1.20274,"marketCap":36619410},{"date":"2025-01-24","current":-1.335088,"twenty":-1.87928,"median":-1.335088,"eighty":-1.207384,"marketCap":36303725},{"date":"2025-01-31","current":-1.288651,"twenty":-1.676407,"median":-1.329284,"eighty":-1.218206,"marketCap":35040987},{"date":"2025-02-07","current":-1.416355,"twenty":-1.657832,"median":-1.323479,"eighty":-1.225421,"marketCap":38513517},{"date":"2025-02-14","current":-1.335088,"twenty":-1.648544,"median":-1.323479,"eighty":-1.239294,"marketCap":36303725},{"date":"2025-02-21","current":-1.288651,"twenty":-1.616038,"median":-1.323479,"eighty":-1.250654,"marketCap":35040987},{"date":"2025-02-28","current":-1.207384,"twenty":-1.525484,"median":-1.317674,"eighty":-1.232138,"marketCap":32831195},{"date":"2025-03-07","current":-1.160946,"twenty":-1.444218,"median":-1.31187,"eighty":-1.207384,"marketCap":31568457},{"date":"2025-03-14","current":-1.07968,"twenty":-1.411711,"median":-1.30026,"eighty":-1.1772,"marketCap":29358665},{"date":"2025-03-21","current":-1.335088,"twenty":-1.404745,"median":-1.30026,"eighty":-1.16559,"marketCap":36303725},{"date":"2025-03-28","current":-1.637559,"twenty":-1.525484,"median":-1.31187,"eighty":-1.1772,"marketCap":44528506},{"date":"2025-04-04","current":-0.76585,"twenty":-1.525484,"median":-1.306065,"eighty":-1.160946,"marketCap":44060874},{"date":"2025-04-11","current":-0.564318,"twenty":-1.462793,"median":-1.288651,"eighty":-1.14388,"marketCap":32466352},{"date":"2025-04-17","current":-0.581158,"twenty":-1.453505,"median":-1.288651,"eighty":-1.129154,"marketCap":33435158},{"date":"2025-04-25","current":-0.632466,"twenty":-1.414033,"median":-1.288651,"eighty":-1.081468,"marketCap":36387058},{"date":"2025-05-02","current":-0.741567,"twenty":-1.404745,"median":-1.288651,"eighty":-1.054291,"marketCap":42663825},{"date":"2025-05-09","current":-0.787263,"twenty":-1.404745,"median":-1.277041,"eighty":-0.791089,"marketCap":45292790},{"date":"2025-05-16","current":-0.737114,"twenty":-1.402423,"median":-1.253822,"eighty":-0.755291,"marketCap":43209631},{"date":"2025-05-23","current":-0.783669,"twenty":-1.393136,"median":-1.253822,"eighty":-0.759832,"marketCap":45938661},{"date":"2025-05-30","current":-0.771642,"twenty":-1.393136,"median":-1.251182,"eighty":-0.76585,"marketCap":45233661},{"date":"2025-06-06","current":-1.017762,"twenty":-1.393136,"median":-1.225421,"eighty":-0.767335,"marketCap":59661197},{"date":"2025-06-13","current":-1.009213,"twenty":-1.381526,"median":-1.207384,"eighty":-0.771254,"marketCap":59160042},{"date":"2025-06-20","current":-0.947842,"twenty":-1.372239,"median":-1.207384,"eighty":-0.771564,"marketCap":55562472},{"date":"2025-06-27","current":-1.038117,"twenty":-1.360629,"median":-1.184165,"eighty":-0.771642,"marketCap":60854420},{"date":"2025-07-03","current":-1.017762,"twenty":-1.358307,"median":-1.160946,"eighty":-0.77653,"marketCap":59661197},{"date":"2025-07-11","current":-1.139893,"twenty":-1.351342,"median":-1.160017,"eighty":-0.782117,"marketCap":66820540},{"date":"2025-07-18","current":-1.185692,"twenty":-1.346698,"median":-1.152239,"eighty":-0.783669,"marketCap":69505294},{"date":"2025-07-25","current":-1.231492,"twenty":-1.339732,"median":-1.160017,"eighty":-0.783669,"marketCap":72190048},{"date":"2025-08-01","current":-1.129716,"twenty":-1.335088,"median":-1.160248,"eighty":-0.785825,"marketCap":66223928},{"date":"2025-08-08","current":-1.10936,"twenty":-1.335088,"median":-1.151155,"eighty":-0.789762,"marketCap":65030704},{"date":"2025-08-15","current":-1.213067,"twenty":-1.335088,"median":-1.150071,"eighty":-0.791428,"marketCap":70691504},{"date":"2025-08-22","current":-1.177087,"twenty":-1.335088,"median":-1.151155,"eighty":-0.791428,"marketCap":68594722},{"date":"2025-08-29","current":-1.287434,"twenty":-1.335088,"median":-1.160248,"eighty":-0.791428,"marketCap":75025207},{"date":"2025-09-05","current":-1.384803,"twenty":-1.335088,"median":-1.160946,"eighty":-0.797415,"marketCap":80699383},{"date":"2025-09-12","current":-1.525447,"twenty":-1.342054,"median":-1.174821,"eighty":-0.822134,"marketCap":88895414},{"date":"2025-09-19","current":-1.611997,"twenty":-1.365273,"median":-1.182227,"eighty":-0.876364,"marketCap":93939125},{"date":"2025-09-26","current":-1.860829,"twenty":-1.384803,"median":-1.184928,"eighty":-0.929339,"marketCap":108439795},{"date":"2025-10-03","current":-1.947379,"twenty":-1.400101,"median":-1.195775,"eighty":-0.939944,"marketCap":113483507},{"date":"2025-10-10","current":-2.152936,"twenty":-1.42988,"median":-1.207384,"eighty":-0.94314,"marketCap":125462322},{"date":"2025-10-17","current":-2.174573,"twenty":-1.477844,"median":-1.207384,"eighty":-0.951343,"marketCap":126723249},{"date":"2025-10-24","current":-2.163754,"twenty":-1.521119,"median":-1.217191,"eighty":-0.957164,"marketCap":126092786},{"date":"2025-10-31","current":-2.131298,"twenty":-1.627334,"median":-1.225421,"eighty":-0.958345,"marketCap":124201394},{"date":"2025-11-07","current":-2.196211,"twenty":-1.661499,"median":-1.23256,"eighty":-0.960734,"marketCap":127984177},{"date":"2025-11-14","current":-2.001473,"twenty":-1.74585,"median":-1.242213,"eighty":-0.964942,"marketCap":116635827},{"date":"2025-11-21","current":-1.951541,"twenty":-1.828372,"median":-1.253822,"eighty":-0.975077,"marketCap":133100921},{"date":"2025-11-28","current":-2.153773,"twenty":-1.878321,"median":-1.253822,"eighty":-0.98727,"marketCap":146893763},{"date":"2025-12-05","current":-2.254889,"twenty":-1.925381,"median":-1.265432,"eighty":-0.988735,"marketCap":153790183},{"date":"2025-12-12","current":-2.467233,"twenty":-1.950709,"median":-1.277041,"eighty":-0.996674,"marketCap":168272667},{"date":"2025-12-19","current":-2.002099,"twenty":-2.002099,"median":-1.288651,"eighty":-1.007767,"marketCap":136549131},{"date":"2025-12-26","current":-2.062768,"twenty":-2.022322,"median":-1.288651,"eighty":-1.0085,"marketCap":140686984},{"date":"2026-01-02","current":-2.032433,"twenty":-2.02248,"median":-1.288651,"eighty":-1.00907,"marketCap":138618058},{"date":"2026-01-09","current":-2.022322,"twenty":-2.035652,"median":-1.288651,"eighty":-1.009619,"marketCap":137928416},{"date":"2026-01-16","current":-2.103215,"twenty":-2.062768,"median":-1.30026,"eighty":-1.016154,"marketCap":143445552},{"date":"2026-01-23","current":-2.527902,"twenty":-2.079519,"median":-1.303662,"eighty":-1.017762,"marketCap":172410520},{"date":"2026-01-30","current":-2.527902,"twenty":-2.105793,"median":-1.31187,"eighty":-1.017762,"marketCap":172410520},{"date":"2026-02-06","current":-2.608795,"twenty":-2.126582,"median":-1.317674,"eighty":-1.019861,"marketCap":177927656},{"date":"2026-02-13","current":-3.427836,"twenty":-2.136977,"median":-1.323479,"eighty":-1.031375,"marketCap":233788665},{"date":"2026-02-20","current":-3.609844,"twenty":-2.149226,"median":-1.323479,"eighty":-1.038117,"marketCap":246202222},{"date":"2026-02-27","current":-3.630068,"twenty":-2.153773,"median":-1.330709,"eighty":-1.044184,"marketCap":247581506},{"date":"2026-03-06","current":-4.823238,"twenty":-2.163754,"median":-1.335088,"eighty":-1.055298,"marketCap":328959272},{"date":"2026-03-13","current":-6.821589,"twenty":-2.163832,"median":-1.335088,"eighty":-1.05838,"marketCap":338289413},{"date":"2026-03-20","current":-6.571003,"twenty":-2.174573,"median":-1.340893,"eighty":-1.062543,"marketCap":325862626},{"date":"2026-03-27","current":-6.48492,"twenty":-2.196211,"median":-1.358307,"eighty":-1.072721,"marketCap":321593683},{"date":"2026-04-02","current":-6.728822,"twenty":-2.279157,"median":-1.369917,"eighty":-1.078827,"marketCap":333689021},{"date":"2026-04-10","current":-7.890943,"twenty":-2.31549,"median":-1.383164,"eighty":-1.078974,"marketCap":391319747},{"date":"2026-04-17","current":-8.249622,"twenty":-2.347317,"median":-1.393136,"eighty":-1.079587,"marketCap":409107008},{"date":"2026-04-24","current":-7.474875,"twenty":-2.424764,"median":-1.39894,"eighty":-1.079843,"marketCap":370686524},{"date":"2026-05-01","current":-7.357517,"twenty":-2.49456,"median":-1.404745,"eighty":-1.081468,"marketCap":364866631},{"date":"2026-05-08","current":-7.717474,"twenty":-2.527902,"median":-1.450845,"eighty":-1.086096,"marketCap":382717249},{"date":"2026-05-15","current":-3.318654,"twenty":-2.605325,"median":-1.471353,"eighty":-1.089005,"marketCap":354870285},{"date":"2026-05-22","current":-2.864592,"twenty":-2.625631,"median":-1.50381,"eighty":-1.089833,"marketCap":306316604},{"date":"2026-05-29","current":-2.804496,"twenty":-2.764432,"median":-1.520037,"eighty":-1.093147,"marketCap":299890382},{"date":"2026-06-05","current":-3.098301,"twenty":-2.804496,"median":-1.567278,"eighty":-1.099183,"marketCap":331307470},{"date":"2026-06-12","current":-2.976252,"twenty":-2.841362,"median":-1.641006,"eighty":-1.10936,"marketCap":318256557},{"date":"2026-06-18","current":-3.09043,"twenty":-2.862186,"median":-1.648544,"eighty":-1.10936,"marketCap":330465888},{"date":"2026-06-26","current":-2.831626,"twenty":-2.921273,"median":-1.671763,"eighty":-1.117502,"marketCap":302791405},{"date":"2026-07-02","current":-3.181773,"twenty":-2.964753,"median":-1.703207,"eighty":-1.119538,"marketCap":340233353},{"date":"2026-07-10","current":-3.103979,"twenty":-3.005472,"median":-1.779688,"eighty":-1.123486,"marketCap":331914656},{"date":"2026-07-17","current":-2.5326,"twenty":-2.998741,"median":-1.85001,"eighty":-1.127372,"marketCap":270815938},{"date":"2026-07-24","current":-2.254631,"twenty":-2.977774,"median":-1.874663,"eighty":-1.129113,"marketCap":241092238},{"date":"2026-07-31","current":-2.964995,"twenty":-2.973207,"median":-1.900983,"eighty":-1.129716,"marketCap":317052806},{"date":"2026-08-07","current":-2.854241,"twenty":-2.967182,"median":-1.931317,"eighty":-1.129716,"marketCap":307144906},{"date":"2026-08-14","current":-2.87602,"twenty":-2.967182,"median":-1.947379,"eighty":-1.129716,"marketCap":309488461},{"date":"2026-08-21","current":-3.185269,"twenty":-2.973207,"median":-1.951541,"eighty":-1.129716,"marketCap":342766790},{"date":"2026-08-28","current":-2.976526,"twenty":-2.991855,"median":-1.986619,"eighty":-1.13016,"marketCap":320303918},{"date":"2026-09-04","current":-3.556368,"twenty":-3.015947,"median":-2.002099,"eighty":-1.13167,"marketCap":382700785},{"date":"2026-09-11","current":-4.69286,"twenty":-3.069117,"median":-2.01221,"eighty":-1.133546,"marketCap":504998645}],"updateTime":1789386128373},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IRD\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2631763180","title":"Piper Sandler Sticks to Its Buy Rating for Opus Genetics (IRD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2631763180","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631763180?lang=en_us&edition=fundamental","pubTime":"2026-04-30 19:40","pubTimestamp":1777549228,"startTime":"0","endTime":"0","summary":"In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Opus Genetics, with a price target of $11.00. According to Tip...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-its-buy-rating-for-opus-genetics-ird-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-its-buy-rating-for-opus-genetics-ird-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630838015","title":"Opus Genetics Initiated at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2630838015","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630838015?lang=en_us&edition=fundamental","pubTime":"2026-04-28 22:03","pubTimestamp":1777384980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IRD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 28, 2026 10:03 ET (14:03 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IRD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630537918","title":"Opus Genetics initiated with an Outperform at Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2630537918","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630537918?lang=en_us&edition=fundamental","pubTime":"2026-04-28 16:45","pubTimestamp":1777365912,"startTime":"0","endTime":"0","summary":"Citizens initiated coverage of Opus Genetics (IRD) with an Outperform rating and $12 price target The company is developing a portfolio of AAV-base...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/opus-genetics-initiated-with-an-outperform-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/opus-genetics-initiated-with-an-outperform-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630746396","title":"Opus Genetics to present at ARVO annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2630746396","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630746396?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:09","pubTimestamp":1777291795,"startTime":"0","endTime":"0","summary":"Opus Genetics leadership plans to attend Retinal Therapeutics Innovation Summit on May 1, 2026 in Denver.Opus Genetics plans to attend ASGCT Annual Meeting on May 11-15, 2026 in Boston.Company plans to attend Retina World Congress on May 14-17, 2026 in Fort Lauderdale.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL4qHyPg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4112","LU2210149790.SGD","LU2210150020.SGD","SG9999014021.USD","IE00BN0W2T93.GBP","BK4139","BK4007","LU0314104364.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","NDAQ","IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4588","IE00BN0W2V16.EUR","SG9999014005.SGD","BK4585","SG9999014039.USD","SG9999014013.SGD","IE00B3QW5Z07.USD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630820502","title":"Opus Genetics enters senior secured note deal for up to $155 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2630820502","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630820502?lang=en_us&edition=fundamental","pubTime":"2026-04-25 05:08","pubTimestamp":1777064937,"startTime":"0","endTime":"0","summary":"Opus Genetics entered senior secured note purchase agreement with OPCM SA LLC as purchaser agent for issuance of up to USD 155 million of senior secured notes.Purchasers committed to buy USD 105 million, leaving USD 50 million uncommitted.Initial tranche of USD 35 million funded April 21, 2026, with notes issued at par.Initial Tranche Notes mature April 21, 2033, with floating interest tied to Term SOFR subject to floor.Notes secured by substantially all assets of Opus Genetics and subsidiaries, with guarantees from certain subsidiaries.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval syste","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDL6xRd6Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","BK4023","IRD","LU0757428866.USD","BK4007","BK4139","LU1815336091.USD","WK","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629073826","title":"Barinthus Biotherapeutics appoints Douglas Swirsky as CFO effective May 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2629073826","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629073826?lang=en_us&edition=fundamental","pubTime":"2026-04-23 04:45","pubTimestamp":1776890707,"startTime":"0","endTime":"0","summary":"Barinthus Biotherapeutics appointed Douglas Swirsky as chief financial officer, effective May 1, 2026.Swirsky will also serve as principal accounting officer.He was CFO of MaxCyte from March 2023 to March 2026.Swirsky previously served as CFO and treasurer of AavantiBio until its December 2022 acquisition by Solid Biosciences.Earlier roles include CEO of Rexahn Pharmaceuticals from November 2018 to November 2020.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Barinthus Biotherapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 22, 2026, and is solely responsible for the inf","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL2RDlL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","IRD","MXCT","BK4007","BK4539","SLDB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629121520","title":"Opus Genetics shareholders approved authorized common stock increase to 250 million shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2629121520","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629121520?lang=en_us&edition=fundamental","pubTime":"2026-04-22 18:17","pubTimestamp":1776853039,"startTime":"0","endTime":"0","summary":"Opus Genetics annual stockholders meeting was held on April 20, 2026.Stockholders elected nine directors to one-year terms ending at 2027 annual meeting.Amendment to restated certificate of incorporation to increase authorized common shares to 250 million from 125 million was adopted.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL6hwYCc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IRD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627357447","title":"Analysts Are Bullish on Top Healthcare Stocks: Opus Genetics (IRD), Argenx Se (ARGX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2627357447","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627357447?lang=en_us&edition=fundamental","pubTime":"2026-04-14 22:32","pubTimestamp":1776177133,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Opus Genetics (IRD), Argenx Se (ARGX) and Xtant Medi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-opus-genetics-ird-argenx-se-argx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-opus-genetics-ird-argenx-se-argx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","LU0109394709.USD","IE0009355771.USD","BK4139","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4585","LU1983260115.SGD","BK4112","IE0034235188.USD","BK4581","LU0889565916.HKD","BLSX","IE00BJJMRZ35.SGD","LU0128526141.USD","BK4137","LU2324357040.USD","IE0002141913.USD","BK4007","IE00B2B36J28.USD","LU0029874061.USD","BK4505","IRD","XBI","BLSG","IE00B4R5TH58.HKD","BK4588","ARGX","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626191003","title":"Opus Genetics to present Phase 3 VEGA-3 presbyopia data at ASCRS meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2626191003","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626191003?lang=en_us&edition=fundamental","pubTime":"2026-04-10 18:59","pubTimestamp":1775818778,"startTime":"0","endTime":"0","summary":"Opus Genetics flagged full results from VEGA-3 Phase 3 study of phentolamine ophthalmic solution 0.75% for presbyopia for presentation at ASCRS annual meeting in Washington, D.C., April 10-13, 2026.Data set is positioned as showing durable improvement in near vision for presbyopic patients, without disclosing detailed metrics in this announcement.Company also scheduled a Phase 3 post-hoc analysis from MIRA-2 on RYZUMVI for reversing pharmacologically induced mydriasis, focused on image-quality impact.Encore Phase 3 LYNX-2 presentation is set to cover phentolamine use for low-light visual disturbances in post-refractive surgery patients.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL8JtmbN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IRD","SG9999014005.SGD","IE00BN0W2W23.USD","NDAQ","SG9999014039.USD","IE00BKPKM429.USD","LU2095319765.USD","BK4588","SG9999014021.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4139","LU2210150020.SGD","BK4007","BK4112","SG9999014013.SGD","BK4585","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625325809","title":"Opus Genetics offers executives excise tax reimbursement under change-in-control bonus agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2625325809","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625325809?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:01","pubTimestamp":1775559717,"startTime":"0","endTime":"0","summary":"Opus Genetics entered change-in-control bonus payment agreements on April 1, 2026, covering CEO Dr. George Magrath, CFO Robert Gagnon, COO Joseph Schachle.Agreements provide reimbursement for executives’ excise taxes triggered by a change in control under Internal Revenue Code Section 4999.Chief Scientific and Development Officer Dr. Ashwath Jayagopal also covered under same arrangement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 07, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL3v2L10:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IRD","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625934159","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Opus Genetics (IRD) and IQVIA Holdings (IQV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2625934159","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625934159?lang=en_us&edition=fundamental","pubTime":"2026-04-07 18:40","pubTimestamp":1775558423,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Opus Genetics (IRD) and IQVIA Holdings (IQV). Opus Genetics (IRD)...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-opus-genetics-ird-and-iqvia-holdings-iqv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-opus-genetics-ird-and-iqvia-holdings-iqv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1201861249.SGD","BK4007","LU0130102774.USD","LU0130103400.USD","LU0130517989.USD","BK4121","LABU","LU0528227936.USD","LU1791710582.SGD","BK4581","LU0198837287.USD","LU0648001328.SGD","LU0477156797.USD","BK4585","LU0882574055.USD","IQV","LU1791710400.SGD","LU0029874061.USD","BK4139","LU0128526141.USD","IRD","LU0648000940.SGD","BK4137","LU0130518102.USD","LU1201861165.SGD","BK4588","LU1261432733.SGD","LU0980610538.SGD","LU0477156953.USD","XLV","BK4530","HCSG","LU1989764664.SGD","LU1989764748.USD","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625676665","title":"BRIEF-Opus Genetics Inc Announced Strategic Financing Agreement With Oberland Capital Management Llc","url":"https://stock-news.laohu8.com/highlight/detail?id=2625676665","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625676665?lang=en_us&edition=fundamental","pubTime":"2026-04-06 19:16","pubTimestamp":1775474192,"startTime":"0","endTime":"0","summary":"BRIEF-Opus Genetics Inc Announced Strategic Financing Agreement With Oberland Capital Management LlcApril 6 (Reuters) - Opus Genetics Inc IRD.O:OPUS GENETICS INC: ANNOUNCED STRATEGIC FINANCING AGREEME","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40M029:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IRD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625763326","title":"Opus Genetics Inc - Cash Runway Extended Into 2029 With $100 Mln Cash","url":"https://stock-news.laohu8.com/highlight/detail?id=2625763326","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625763326?lang=en_us&edition=fundamental","pubTime":"2026-04-06 19:03","pubTimestamp":1775473380,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40M029:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","IRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625676845","title":"Opus Genetics Inc - New Note Facility Provides Access to Upto $155 Mln Non-Dilutive Funding With $35 Mln Upfront","url":"https://stock-news.laohu8.com/highlight/detail?id=2625676845","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625676845?lang=en_us&edition=fundamental","pubTime":"2026-04-06 19:03","pubTimestamp":1775473380,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40M029:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IRD","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625676351","title":"Opus Genetics Inc - up to 10% of Notes Convertible, at Oberland Capital’s Option, Into Co's Stock at $6.72 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2625676351","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625676351?lang=en_us&edition=fundamental","pubTime":"2026-04-06 19:03","pubTimestamp":1775473380,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40M029:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IRD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625667635","title":"Opus Genetics Inc:  Oberland Capital Committed to Make a $5 Mln Equity Investment in Co's Stock at $4.48/Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2625667635","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625667635?lang=en_us&edition=fundamental","pubTime":"2026-04-06 19:03","pubTimestamp":1775473380,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40M029:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","IRD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625750246","title":"Opus Genetics secures up to $155 million Oberland Capital non-dilutive financing facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2625750246","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625750246?lang=en_us&edition=fundamental","pubTime":"2026-04-06 19:00","pubTimestamp":1775473248,"startTime":"0","endTime":"0","summary":"Opus Genetics entered strategic financing agreement with Oberland Capital for up to $155 million in non-dilutive funding.Facility provides $35 million initial note tranche, expected to close April 20, 2026.Oberland Capital committed $5 million equity investment at $4.48 per share, expected to close concurrently.Cash resources of about $100 million extend runway into 2029, covering expected completion of OPGx-LCA5 and OPGx-BEST1 pivotal studies.Notes mature seven years from initial issuance; initial cash interest rate at closing about 4.1%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDL5x3yY9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4112","IRD","IE00BKPKM429.USD","LU2095319765.USD","BK4007","LU0314104364.USD","LU2210149790.SGD","BK4139","BK4588","NDAQ","SG9999014039.USD","IE00BN0W2T93.GBP","BK4585","IE00BN0W2W23.USD","SG9999014021.USD","SG9999014013.SGD","IE00B64PRP62.GBP","SG9999014005.SGD","IE00B3QW5Z07.USD","LU2210150020.SGD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623128773","title":"Cantor Fitzgerald Initiates Opus Genetics at Overweight With $15 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2623128773","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623128773?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:43","pubTimestamp":1774871026,"startTime":"0","endTime":"0","summary":"Opus Genetics, Inc. (IRD) has an average rating of buy and mean price target of $10.08, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7129","IRD.AU","IRD","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623431416","title":"Opus Genetics Initiated at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2623431416","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623431416?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:29","pubTimestamp":1774870140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IRD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 30, 2026 07:29 ET (11:29 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IRD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622050016","title":"Bremworth Secures IRD Clearance in Floorscape Acquisition Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2622050016","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622050016?lang=en_us&edition=fundamental","pubTime":"2026-03-25 06:09","pubTimestamp":1774390188,"startTime":"0","endTime":"0","summary":"Bremworth  has received a binding New Zealand tax ruling from the Inland Revenue Department  on its proposed capital return, clearing a key step in Floorscape's planned acquisition of all the company shares, according to a Wednesday filing with the New Zealand bourse.The ruling satisfies a key condition under the scheme implementation agreement, but the scheme remains subject to other requirements, including clearance from the New Zealand Commerce Commission, approval by the company shareholders, and final high court approval, per the filing.The company said shareholders do not need to take any action at this stage, as reported in the filing.The company's shares fell around 2% in recent Wednesday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7129","BK4007","IRD.AU","IRD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":6,"totalSize":121,"code":"91000000","status":"200"}]}}